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Background: Currently, staging of head neck squamous cell carcinoma (HNSCC) is on the basis of primary tumor
extension (cT), lymph node involvement (cN) and distant metastasis (cM). The aim of cancer staging was to improve
diagnosis, prognosis and to compare outcome results. A new subgroup of oropharyngeal squamous cell carcinoma
(OPSCC) induced by human papillomavirus (HPV) infection is reported to show an increasing incidence. These HPV-
positive OPSCC show distinct molecular differences, specific p16 overexpression and a significantly better prognosis.
Therefore, the aim of this study was to evaluate the prognostic influence of p16 expression in OPSCC and compare its
relevance with the established prognostic markers cT and cN classification and the clinical stages I–IV.
Patients and methods: Immunohistochemistry for p16 was carried out on the basis of a tissue microarray including
102 OPSCC patients with corresponding retrospective clinicopathological and follow-up data.
Results: p16 is the strongest independent prognostic marker in OPSCC, surpassing the significance of cT and cN
classification as well as the clinical stages I–IV. Prognosis of p16-positive OPSCC of an advanced stage reached or
even exceeded prognosis of the next clinically smaller conventionally staged group of tumors.
Conclusion: p16 is the most relevant prognostic marker in OPSCC and should be considered for inclusion into the
official staging system of HNSCC.
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introduction
The aim of cancer classification is to better understand
prognosis of cancer, to improve diagnosis and compare
outcome results for a consecutive improvement of treatment
recommendations of distinct cancers at a specific stage of
disease. Current staging of head neck squamous cell carcinoma
(HNSCC) is primarily based on clinical primary tumor
extension (cT), lymph node involvement (cN) and distant
metastasis (cM). For surgically treated tumors, two
histopathological parameters tumor grading (G) and radicality
of resection (R) are added. Risk factors for locoregional relapse
such as vascular invasion (V), lymph node capsular spread and
tumor-free margin size of the resected tumor were recently
identified. Locoregional control is significantly improved when
these HNSCC patients are treated with postoperative
concurrent radiotherapy (RT) with platinum-based
chemotherapy [1, 2]. Currently, no parameters representing
information neither on tumor biology nor on tumor behavior
under therapy are included nor in HNSCC staging nor for
treatment modality choice. Small tumor stages I and II,
including primary tumors <4 cm without locoregional lymph
node metastases, are treated by single modalities, surgery or RT
alone, whereas advanced tumor stages III and IV undergo
a combined modality treatment with either radical surgery plus
adjuvant RT or concomittant radiochemotherapy (RCT),
combined with a platinum-based chemotherapy.
Cancer statistics report an increased incidence of oral and
oropharyngeal squamous cell carcinoma (OPSCC) in the
United States as well as in Europe [3–5]. This subgroup of
OPSCC is characterized by human papillomavirus (HPV) 16 or
18 infections leading to distinct molecular characteristics and
indicating a different pathway in carcinogenesis compared with
HPV-negative HNSCC [6]. One particular molecular
difference, among others, concerns p16 expression. Nuclear and
cytoplasmic p16 overexpressions correlate precisely with HPV
positivity and are indicated to be specific for HPV-positive
OPSCC [7, 8]. Patients with OPSCC overexpressing HPV with
or without p16 overexpression as well as those p16-positive
OPSCC without HPV detection show a significantly improved
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prognosis when compared with patients with HPV- and p16-
negative OPSCC [9], independent of the treatment modality
chosen [6, 10–16].
In this study, we evaluate the prognostic influence of p16
expression in OPSCC and compare its relevance with the
established prognostic markers cT and cN classification and the
clinical stages I–IV. The importance of p16 status in OPSCC
staging may be of decisive importance for staging as well as for
treatment recommendations in the near future.
materials and methods
patient data and specimen characteristics
At the University Hospital in Basel, we constructed a tissue microarray
(TMA) of previously untreated samples with complete medical history and
follow-up data [17]. Hundred and two of the tumor specimens were located
in the oropharynx. Small tumors with stages I and II were treated by single
modality, either surgery or RT, advanced tumor stages III and IV with
combined modalities, either surgery plus adjuvant RT or RCT.
Median follow-up time was 48.5 months and overall 5-year survival rate
(5-YSR) was 38% [95% confidence interval (CI) 28% to 48%]. Censored
observations included patients who were alive at last possible follow-up. Of
102 patients evaluated, 68 patients (66.7%) died of disease and 34 (33.3%)
were considered censored. Clinicopathological data are summarized in
Table 1.
immunohistochemical p16 analysis
For the immunohistochemical p16 staining and scoring, we followed the
previously described procedure [13]. Failure of analysis (7% of all cases, 8
from 110 samples) was related to TMA technology, including a fraction of
missing samples (empty spot) and those spots containing no or only a few
tumor cells.
statistical analysis methods
The association of p16 expression (negative <5% and positive ‡5%
immunoreactivity in tumor cells) with clinicopathological features was
carried out by the chi-square test, Fisher’s exact test and Student’s t-test,
where appropriate. Univariate tumor-specific survival and recurrence-free
survival were evaluated by the Kaplan–Meier method and log-rank test. The
appropriate number of variables to be included into multivariable survival
analysis using multiple Cox regression models was on the basis of the
number of patient deaths. In order to prevent overfitting, we considered
one variable per 10 patient deaths. Therefore, the prognostic impact of p16
expression in stage IV patients alone (n = 44 deaths) and stages III and IV
patients (n = 59 deaths) was considered along with cT, cN and tumor
grading. The hazard ratio (HR) and 95% CIs were obtained in order to
determine the effect of each variable on outcome with HR < 1.0, indicating
a negative effect on outcome with p16 positivity. The assumption of
proportional hazards was first verified by analyzing the correlation of
Schoenfeld residuals and the ranks of individual failure times. P values <
0.05 were considered statistically significant. All analyses were carried out
using SAS (Version 9; Cary, NC).
results
patients
Distribution of the most relevant clinicopathological
parameters between the p16-positive and -negative OPSCC is
shown in Table 1. No significant differences were found; the
proportion of larger primary tumors grew in favor of the p16-
negative OPSCC.
clinical staging parameters and overall survival
As the group of small OPSCC stages I and II included only 8
and 14 patients, respectively, these stages were analyzed
together. Overall survival of the small stage tumors was
significantly longer than that of the advanced stages (P = 0.02).
5-YSR for these was 63.3% (95% CI 39% to 80%) compared
with 31% (95% CI 11% to 52%) for stage III, similar to stage IV
[29.5% (95% CI 19% to 41%)] (Figure 1, panel A). The
prognostic impact of the most relevant clinical prognostic
parameter—cN classification, a significantly better overall
survival for nodal-negative tumors with a 5-YSR of 56% (95%
CI 35% to 72%) compared with 30% (95% CI 20% to 41%) for
nodal-positive OPSCC (P = 0.0097) (data not shown). Among
the advanced OPSCC, overall survival of stages III and IV
depended highly on cT classification, tumors >4 cm had
a significantly worse prognosis (P = 0.001) (Figure 1, panel C).
No relevant influence was seen considering cN classification:
as there were three OPSCC with cN0 classification, samples
were grouped cN0 with cN1 versus cN2 with cN3
tumors. No differentiation in overall survival was achieved,
5-YSR was 27.9% and 30.7%, respectively (P = 0.915)
(Figure 1, panel D).
Table 1. Clinicopathological parameters in 102 oropharyngeal
squamous cell carcinomas
p16, n (%) P value
Positive Negative
Gender
Female 12 (29) 11 0.183
Male 29 (71) 50
Age, median (range) (years) 60.4 (39–78) 58 (36–91) 0.232
Tumor localization
Palatine tonsil 19 (46) 28 (46) 0.32
Soft palate 3 (7) 11 (18)
Base of the tongue 16 (40) 16 (26)
Back wall 3 (7) 6 (10)
cT classification
cT1 9 (22) 10 (16) 0.189
cT2 22 (54) 24 (39)
cT3 6 (14) 12 (20)
cT4 4 (10) 15 (25)
cN classification
cN0 11 (26) 15 (25) 0.398
cN1 8 (20) 13 (21)
cN2 22 (54) 29 (48)
cN3 0 (0) 4 (6)
c Stage
Stage I 3 (7) 5 (8) 0.99
Stage II 6 (15) 8 (13)
Stage III 8 (20) 11 (18)
Stage IV 24 (56) 37 (61)
Tumor grading
Grade 1 1 (2) 4 (6) 0.646
Grade 2 23 (56) 37 (61)
Grade 3 17 (42) 20 (33)
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p16 expression and overall survival
Summarizing all four stages, p16-positive OPSCC had
a better prognosis, 5-YSR 59.3% (95% CI 41% to 73%), than
p16-negative tumors with 24.5% (95% CI 14% to 36%) (P =
0.0008) (Figure 1, panel B). This effect is seen even stronger in
the advanced OPSCC stages III and IV: p16-positive tumors
showed a 5-YSR of 54.1% (95% CI 34% to 71%) compared
with 18% (95% CI 9% to 30%) for p16-negative OPSCC (P =
0.0002) (Figure 1, panel E). The p16-positive subgroup of the
advanced stages III and IV showed the similar good overall
survival as the small stages I and II with a 5-YSR of 59.4% (95%
CI 34% to 78%) (P = 0.55) (Figure 1, panel F). Dividing the
Figure 1. Kaplan–Meier survival curves of 102 oropharyngeal squamous cell carcinoma showing the overall survival differences between (A) the different
clinical stages I + II, III and IV; (B) the p16-positive and p16-negative tumors, all stages included; (C) the primary tumor classifications cT1/2 and cT3/4 in
the advanced stages III and IV; (D) the lymph node metastasis classifications cN0/1 and cN2/3 in the advanced stages III and IV; (E) the p16-positive and
p16-negative advanced stages III and IV; (F) all the clinical stages I and II tumors and the p16-positive advanced stages III and IV; (G) the p16-positive and
p16-negative advanced stage IV tumors; and (H) all the clinical stage III tumors and the p16-positive advanced tumors stage IV.
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advanced stages in stages III and IV tumors, patients with p16-
positive stage IV tumors survive 5 years in 59.2% (95% CI 36%
to 77%) compared with 18.9% (95% CI 8% to 33%) for p16-
negative stage IV OPSCC (P = 0.0003) (Figure 1, panel G).
Patients with p16-positive stage IV OPSCC survived
significantly longer than those conventionally staged III
OPSCC, 5-YSR 32.5% (95% CI 13% to 55%) (P = 0.048)
(Figure 1, panel H).
The impact of the clinical parameters and p16 expression in
the advanced stages III and IV was analyzed and compared in
a multivariable analysis (Table 2), demonstrating the strongest
prognostic effect of p16, which is independent of the
conventional staging parameters cT and cN classification as
well as tumor grade.
discussion
The first classification of cancer stage was developed from 1943
to 1952 by Professor Pierre Denoix at the Institute Gustave
Roussy in France, later establishing the Union Internationale
Contre le Cancer (UICC). Since the fusion of the UICC and the
American Joint Committee for Cancer in 1987, official and
regularly updated staging guidelines for most malignant tumors
are published. Standardized cancer staging and classification
should lead to a more precise and comprehensive recording of
the neoplastic disease as a reliable basis for comparison of
treatment outcome of a distinct tumor with a defined
extension. Furthermore, these data enable an improvement
toward a more individualized patient-centered treatment.
We analyzed the impact of p16 overexpression in OPSCC.
p16, a cell cycle checkpoint regulator functions as a tumor
suppressor and is located on chromosome 9p21. It is
overexpressed in HPV-positive OPSCC due to the degradation
of pRb by the viral oncoprotein E7 [18, 19], as pRb normally
functions as a negative regulator of p16 expression. Nuclear and
cytoplasmic p16 overexpressions correlate precisely to HPV
positivity in OPSCC and are indicated to be specific for these
carcinomas. As p16 overexpression is very rarely seen in HPV-
negative HNSCC, it is considered a surrogate marker for HPV
positivity in OPSCC [7, 8]. The relevance of the positive
prognostic effect of p16 expression has also been reported in
HPV-negative OPSCC compared with HPV- and p16-negative
tumors [9]. A possible reason could be an induction of p16
expression by E7 at a very early stage of disease, when HPV
cannot yet be detected.
Among the p16-positive and -negative OPSCC, no significant
differences in the distribution of the clinical parameters was
noticed, the p16-negative group including more advanced
primary tumors, a result also presented by others [20].
Although some authors discuss HPV-induced OPSCC as
carcinomas with more frequent lymph node metastases [21,
22], others could find no correlation to cN classification at all
[11, 12], as it was also found in our study. Dividing OPSCC by
clinical stages I–IV showed the expected prognostic division of
the small stages I and II from the advanced stages III and IV.
Similar to published results [21], a much more relevant
division of OPSCC in terms of outcome differences was
achieved not by clinical parameters but by grouping OPSCC in
p16-positive and -negative tumors, the 5-YSR for the p16-
positive OPSCC more than twice the rate of p16-negative
OPSCC.
The advanced stages depend either on large primary tumors
or on lymph node involvement. While primary tumor size had
a highly significant impact on prognosis of stages III and IV
OPSCC, cN classification did not. HPV- or p16-positive
OPSCC is reported to show a more advanced cN classification
lymphatic metastases at an earlier stage of the primary disease
compared with p16-negative OPSCC [21, 22]. This led in our
collective to the inclusion of more small primaries with
advanced cN classifications in the stage IV group and more
advanced primaries in the small stage III group, possible
reasons for their similar long-term outcome (Figure 1A) and
for the limited sample size of the cN0 group, which was too
small to be analyzed separately and summarized with the cN1
tumors. Probably, a stronger differentiation could have been
achieved if the cN0 tumors could be differentiated and
compared separately with cN-positive tumors. Again, the
influence of p16 expression in the advanced stages III and IV
was the most relevant parameter and independent of the other
clinical parameters in a multivariable analysis. Most
interesting, 5-YSR of p16-positive advanced stage OPSCC was
nearly as good as the survival rate of the clinically small stages
I and II (54.1% versus 59.4%). We are aware of the fact that
the advanced staged OPSCC were treated by a combined
modality treatment, whereas small stages were treated either
by surgery or RT alone. Therefore, the same examination
was made among the advanced stages. The whole group was
now treated by combined modalities, surgery plus adjuvant
RT or RCT. p16-positive OPSCC clearly surpassed prognosis
of the stage III tumors, the 5-YSR approaching the double
survival rate of the stage III tumors (59.2% versus 32.6%).
Again, the impact of p16 was shown to be the strongest
prognostic marker in advanced OPSCC and independent of
the clinical parameters in a multivariable analysis for stage IV
tumors. A similar prognostic benefit of p16-expressing
OPSCC was also reported by Weinberger et al. [21], who
could show a significant prognostic effect not only on overall
survival but also on locoregional tumor control and disease-
free survival. Most recently, these data were confirmed in two
large phase III trials: Gillison et al. [23] reported the
prognostic advantage of HPV-positive OPSCC after RCT.
Rischin et al. compared the prognostic effect of the four
different combinations of HPV and p16 expression after RCT.
They showed that the largest group of OPSCC with an
Table 2. Prognostic effect of p16 expression after adjustment for effects
of tumor grade, cT and cN classification in oropharyngeal squamous cell
carcinoma
Feature Stage IV Stages III and IV
P value HR (95% CI) P value HR (95% CI)
p16 positivity 0.006 0.34 (0.2–0.7) 0.002 0.39 (0.2–0.7)
Tumor grade 0.319 1.32 (0.7–2.3) 0.71 0.97 (0.8–1.2)
cT classification 0.073 1.39 (1.0–2.0) 0.005 1.49 (1.1–1.9)
cN classification 0.653 1.18 (0.6–2.4) 0.836 1.05 (0.7–1.6)
95% CI, 95% confidence interval; HR, hazard ratio.
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improved prognosis is identified by p16 positivity alone as
the HPV-negative but p16-positive group of OPSCC had
a better prognosis compared with the HPV- and p16-negative
tumors [9].
A thorough clinical staging evaluation, on which outcome
comparisons and treatment recommendations are based,
involves physical examination, endoscopy and radiological
imaging. Physical examination and endoscopy depend primarily
on the clinicians experience as does radiological imaging by
computed tomography, magnetic resonance tomography or
positron emission tomography depend on the radiologists
interpretation [24]. Clinical and radiological evaluations bear
limits and uncertainties. A corresponding example is the
examination and interpretation of a possible bone invasion of
the mandible by an advanced OPSCC, as bone invasion is a
crucial factor for a cT4 classification of the primary tumor and
a strong argument to treat this tumor by surgery instead of RT.
The lymph node status of HNSCC is prognostically even
more important than the primary tumor size. Staging
evaluation for the cN classification is not defined, clinical
examination with ultrasound of the neck and radiological
imaging are mandatory. But all three methods depend on the
size and shape of the lymph nodes, sensitivity and specificity for
a correct diagnosis of a lymph node metastasis in a cN0 neck
are very low [25]. Despite a precise clinical neck staging, we
miss in up to 30% of the clinically cN0 necks occult nodal
disease, as reported by comparison with elective neck dissection
or sentinel lymph node biopsy [26].
In conclusion, for conventional staging and pretreatment
decision making, we still rely on results achieved by the ‘best’
staging methods/techniques available, in awareness of the bias
included. p16 expression is a very sensitive and specific marker
for HPV infection in HNSCC. p16 immunohistochemistry of
HNSCC is carried out and evaluated in a very standardized
way, it is cheap and easy to carry out also in smaller
pathological centers. Interpretation of p16 expression
furthermore is facilitated, as already 5% of p16 expressing
tumor cells are defined as a positive result, indicating that this
tumor is induced by HPV and has therefore a highly
significantly better prognosis. Various publications reported
this effect in tumors treated as well by surgery [12, 16] as by
RT/RCT [9, 15, 23], it seems to be independent of the
treatment modality chosen [13].
We are aware of the limitations of our study as the small
sample size of evaluated OPSCC in a retrospective analysis.
Despite these limitations, we present outcome data of a single
multidisciplinary head and neck cancer institution, generated
in a standardized way: clinical and radiological evaluation is
coordinated and interpreted at a conjoint tumor board,
treatment regimens chosen corresponding to published official
guidelines. The study design was carried out according to the
REMARK criteria [27] and biopsy specimens analyzed in
a TMA, which allowed us a p16 staining under standardized
circumstances and an evaluation of the immunohistochemistry
by two independent observers.
Based on our and recently published results, we think that it
could be time to reconsider staging of HNSCC and OPSCC
especially, to combine clinical with molecular tumor-based
information to improve validity and relevance of a modern
accurate classification system, on which outcome comparison
and treatment recommendations are built. In our view, future
outcome comparisons of HNSCC and OPSCC, especially,
should distinguish between p16-positive and -negative OPSCC.
Although both tumors are squamous cell carcinomas, they
present two different tumor entities of the same organ. As
undifferentiated outcome results could lead to false prognostic
assumptions for the conventional OPSCC, we recommend to
introduce a third histopathological parameter ‘p16 positive or
negative’ for all OPSCC. This will allow us in the future to
improve treatment of these distinct HPV-positive OPSCCs,
outside the main groups of nicotine- and alcohol-associated
HNSCC, and spare these patients unnecessary treatment-
related short- and long-term side-effects. We are aware,
however, before implementation, our data need validation in
large prognostic series.
disclosure
None of the authors declare conflicts of interest.
references
1. Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without
concomitant chemotherapy for locally advanced head and neck cancer. N Engl J
Med 2004; 350: 1945–1952.
2. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy
and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.
N Engl J Med 2004; 350: 1937–1944.
3. Dahlstrand H, Nasman A, Romanitan M et al. Human papillomavirus accounts
both for increased incidence and better prognosis in tonsillar cancer. Anticancer
Res 2008; 28: 1133–1138.
4. Annertz K, Anderson H, Biorklund A et al. Incidence and survival of squamous
cell carcinoma of the tongue in Scandinavia, with special reference to young
adults. Int J Cancer 2002; 101: 95–99.
5. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma:
increasing trends in the U.S. population ages 20-44 years. Cancer 2005; 103:
1843–1849.
6. Weinberger PM, Yu Z, Haffty BG et al. Molecular classification identifies a subset
of human papillomavirus–associated oropharyngeal cancers with favorable
prognosis. J Clin Oncol 2006; 24: 736–747.
7. Hafkamp HC, Speel EJ, Haesevoets A et al. A subset of head and neck
squamous cell carcinomas exhibits integration of HPV 16/18 DNA and
overexpression of p16INK4A and p53 in the absence of mutations in p53 exons
5-8. Int J Cancer 2003; 107: 394–400.
8. Li W, Thompson CH, O’Brien CJ et al. Human papillomavirus positivity predicts
favourable outcome for squamous carcinoma of the tonsil. Int J Cancer 2003;
106: 553–558.
9. Rischin D, Young R, Fisher R et al. Prognostic significance of HPV and p16 status
in patients with oropharyngeal cancer treated on a large international phase III
trial. J Clin Oncol 2009; 27: 6004.
10. Schwartz SR, Yueh B, McDougall JK et al. Human papillomavirus infection and
survival in oral squamous cell cancer: a population-based study. Otolaryngol
Head Neck Surg 2001; 125: 1–9.
11. Mellin H, Friesland S, Lewensohn R et al. Human papillomavirus (HPV) DNA in
tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer
2000; 89: 300–304.
12. Reimers N, Kasper HU, Weissenborn SJ et al. Combined analysis of HPV-DNA,
p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J
Cancer 2007; 120: 1731–1738.
13. Fischer CA, Zlobec I, Green E et al. Is the improved prognosis of p16 positive
oropharyngeal squamous cell carcinoma dependent of the treatment modality?
Int J Cancer 2010; 126: 1256–1262.
Annals of Oncology original article
Volume 21 |No. 10 | October 2010 doi:10.1093/annonc/mdq210 | 1965
14. Mellin DH, Lindquist D, Bjornestal L et al. P16(INK4a) correlates to human
papillomavirus presence, response to radiotherapy and clinical outcome in
tonsillar carcinoma. Anticancer Res 2005; 25: 4375–4383.
15. Fakhry C, Westra WH, Li S et al. Improved survival of patients with human
papillomavirus-positive head and neck squamous cell carcinoma in a prospective
clinical trial. J Natl Cancer Inst 2008; 100: 261–269.
16. Licitra L, Perrone F, Bossi P et al. High-risk human papillomavirus affects
prognosis in patients with surgically treated oropharyngeal squamous cell
carcinoma. J Clin Oncol 2006; 24: 5630–5636.
17. Sauter G, Simon R, Hillan K. Tissue microarrays in drug discovery. Nat Rev Drug
Discov 2003; 2: 962–972.
18. Wiest T, Schwarz E, Enders C et al. Involvement of intact HPV16 E6/E7 gene
expression in head and neck cancers with unaltered p53 status and perturbed
pRb cell cycle control. Oncogene 2002; 21: 1510–1517.
19. Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the D-type
cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene
product pRb. Cancer Res 1994; 54: 6078–6082.
20. Yuen PW, Man M, Lam KY, Kwong YL. Clinicopathological significance of p16
gene expression in the surgical treatment of head and neck squamous cell
carcinomas. J Clin Pathol 2002; 55: 58–60.
21. Weinberger PM, Yu Z, Haffty BG et al. Prognostic significance of p16 protein levels
in oropharyngeal squamous cell cancer. Clin Cancer Res 2004; 10: 5684–5691.
22. Hafkamp HC, Manni JJ, Haesevoets A et al. Marked differences in survival rate
between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas.
Int J Cancer 2008; 122: 2656–2664.
23. Gillison ML, Harris L, Westra W et al. Survival outcomes by tumor human
papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG
0129. J Clin Oncol 2009; 27: 6003.
24. Ng SH, Yen TC, Liao CT et al. 18F-FDG PET and CT/MRI in oral cavity squamous
cell carcinoma: a prospective study of 124 patients with histologic correlation. J
Nucl Med 2005; 46: 1136–43.
25. de Bondt RB, Nelemans PJ, Hofman PA et al. Detection of lymph node
metastases in head and neck cancer: a meta-analysis comparing US, USgFNAC,
CT and MR imaging. Eur J Radiol 2007; 64: 266–272.
26. van den Brekel MW, van der Waal I, Meijer CJ et al. The incidence of
micrometastases in neck dissection specimens obtained from elective neck
dissections. Laryngoscope 1996; 106: 987–991.
27. McShane LM, Altman DG, Sauerbrei W et al. REporting recommendations for
tumour MARKer prognostic studies (REMARK). Eur J Cancer 2005; 41:
1690–1696.
original article Annals of Oncology
1966 | Fischer et al. Volume 21 |No. 10 |October 2010
